Navigation Links
Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1
Date:7/25/2014

SAN DIEGO, July 25, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it will provide a corporate update and report second quarter 2014 financial results before the NASDAQ Global Select Market opens on Friday, August 1, 2014. That same day, Arena will host a conference call and webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).

The conference call may be accessed by dialing 877.643.7155 for domestic callers and 914.495.8552 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals' Second Quarter 2014 Financial Results Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena PharmaceuticalsArena is embracing the challenge of improving health by seeking to bring innovative medicines targeting G protein-coupled receptors to patients. Arena's internally discovered drug, BELVIQ® (lorcaserin HCl), is approved in the United States, and Arena is focused on discovering, developing and commercializing additional drugs to address unmet medical needs. Arena's US operations are located in San Diego, California, and its operations outside of the United States, including its commercial manufacturing facility, are located in Zofingen, Switzerland. For more information, visit Arena's website at www.arenapharm.com.

Arena Pharmaceuticals® and Arena® are registered service marks of Arena Pharmaceuticals, Inc. BELVIQ® is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking StatementsCertain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about embracing the challenge of improving health; seeking to bring innovative medicines to patients; and Arena's focus, plans, goals, strategy, expectations, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks related to commercializing drugs, including regulatory, manufacturing, supply and marketing issues and the availability and use of BELVIQ; cash and revenues generated from BELVIQ, including the impact of competition; Arena's revenues will be based in part on estimates, judgment and accounting policies, and incorrect estimates or disagreement regarding estimates or accounting policies may result in changes to Arena's guidance or previously reported results; the timing and outcome of regulatory review is uncertain, and BELVIQ may not be approved for marketing when expected or ever in combination with another drug, for another indication or using a different formulation or in any other territory for any indication; regulatory decisions in one territory may impact other regulatory decisions and Arena's business prospects; government and commercial reimbursement and pricing decisions; risks related to relying on collaborative arrangements; the timing and receipt of payments and fees, if any, from collaborators; the entry into or modification or termination of collaborative arrangements; unexpected or unfavorable new data; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to any of Arena's research and development may not meet regulatory requirements or otherwise be sufficient for (or Arena or a collaborator may not pursue) further research and development, regulatory review or approval or continued marketing; Arena's ability to obtain and defend patents; the timing, success and cost of Arena's research and development; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact: Arena Pharmaceuticals, Inc.

Media Contact: Russo PartnersCraig M. Audet, Ph.D., Senior Vice President,  

Operations & Head of Global Regulatory Affairscaudet@arenapharm.com858.453.7200, ext. 1612

David Schull, President

david.schull@russopartnersllc.com

858.717.2310
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Healthcare Companies Announce Drug Launches, Upcoming Conference Calls, and Financial Results Schedules - Research Report on Bristol-Myers Squibb, Teva, Jazz, AmerisourceBergen and Arena
2. Arena Pharmaceuticals to Present at the 32nd Annual J.P. Morgan Healthcare Conference
3. Arena Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
4. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
5. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference
8. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
9. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2013 Financial Results
10. Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, August 1
11. Arena Pharmaceuticals to Present at the 2013 Wells Fargo Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016   Arena Pharmaceuticals, ... that it has completed enrollment in the ralinepag phase ... agonist targeting the prostacyclin pathway for the treatment of ... patients at sites globally. "This marks an ... evidence of our strategic focus on our pipeline," said ...
(Date:12/7/2016)... 2016   Rx Savings Solutions has partnered with ... its Public Employees Insurance Agency (PEIA) to offer more than ... healthcare software, ultimately saving money on their prescriptions. ... members with access to our software that will alert them ... therapy can be found," says Michael Rea , founder ...
(Date:12/7/2016)... India , December 7, 2016 According to ... (Services, Software), Delivery Mode, Product Type (Integrated, Standalone), Model (Knowledge-Based), Type (Therapeutic, ... MarketsandMarkets, The CDSS Market is expected to reach USD 1,519.2 Million by ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Augustine Insurance Agency, a locally ... business owners in the greater Dallas metropolitan area, is announcing a charity event ... , Established in 2009 by active police professionals in the Dallas region, the ...
(Date:12/7/2016)... ... 2016 , ... A. Kevin Spann Insurance, a New York-based firm offering insurance ... launching a charity drive to raise funds that will benefit the Marine Corps League. ... and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
(Date:12/7/2016)... ... 07, 2016 , ... Texas Premier Locksmith , a ... by unethical locksmith companies and is urging Search Engines to improve verification methods ... Premier Locksmith, these fraudulent locksmith services take advantage of consumers locked out of ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors ... said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 ... drop zones. Editors can select from a variety of flip book animations. In Addition, ...
Breaking Medicine News(10 mins):